X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) shares passed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $3.15 and traded as low as $2.98. X4 Pharmaceuticals shares last traded at $3.12, with a volume of 501,341 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, November 3rd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.25.
Check Out Our Latest Stock Analysis on XFOR
X4 Pharmaceuticals Price Performance
The business has a fifty day moving average price of $3.15 and a two-hundred day moving average price of $3.77. The company has a current ratio of 13.22, a quick ratio of 12.86 and a debt-to-equity ratio of 0.55.
X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. X4 Pharmaceuticals had a negative net margin of 474.74% and a negative return on equity of 49.62%. The firm had revenue of $2.88 million for the quarter, compared to analyst estimates of $2.78 million. As a group, equities analysts expect that X4 Pharmaceuticals, Inc. will post -0.67 earnings per share for the current year.
Insider Buying and Selling at X4 Pharmaceuticals
In other news, CFO David Kirske sold 11,767 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total value of $33,653.62. Following the sale, the chief financial officer directly owned 155,983 shares of the company’s stock, valued at approximately $446,111.38. The trade was a 7.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.13% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On X4 Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the stock. SummitTX Capital L.P. acquired a new stake in X4 Pharmaceuticals in the 1st quarter valued at approximately $46,000. Pettinga Financial Advisors LLC purchased a new stake in X4 Pharmaceuticals in the second quarter valued at approximately $47,000. WINTON GROUP Ltd lifted its stake in X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock worth $67,000 after purchasing an additional 3,800 shares in the last quarter. AXQ Capital LP acquired a new position in X4 Pharmaceuticals during the second quarter worth $107,000. Finally, Wellington Management Group LLP acquired a new position in X4 Pharmaceuticals during the second quarter worth $242,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body. Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections. X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia.
Recommended Stories
- Five stocks we like better than X4 Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
